Loading
Life sciences · Journal article
Annals of Coloproctology · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Purpose: The standard treatment for locally advanced rectal cancer involves neoadjuvant chemoradiation followed by total mesorectal excision surgery.A subset of patients achieves pathologic complete response (pCR), representing the optimal treatment outcome.This study compares the long-term oncological outcomes of patients who achieved pCR with those who attained clinical complete response (cCR) after total neoadjuvant therapy, managed using a watch-and-wait approach.Methods: This study retrospectively evaluated patients with mid-low locally advanced rectal cancer who underwent neoadjuvant treatment from January 1, 2005, to May 1, 2023.The pCR and cCR groups were compared based on demographic, clinical, histopathological, and long-term survival outcomes.Results: The median follow-up times were 54 months (range, 7-83 months) for the cCR group (n = 73), 96 months (range, 7-215 months) for the pCR group (n = 63), and 72 months (range, 4-212 months) for the pathological incomplete clinical response (pICR) group (n = 627).In the cCR group, 15 patients (20.5%) experienced local regrowth, and 5 (6.8%) developed distant metastasis (DM).The pCR group had no cases of local recurrence, but 3 patients (4.8%) developed DM.Among the pICR patients, 58 (9.2%) experienced local recurrence, and 92 (14.6%) had DM.Five-year disease-free survival rates were 90.0% for cCR, 92.0% for pCR, and 69.5% for pICR (P = 0.022).Five-year overall survival rates were 93.1% for cCR, 92.0% for pCR, and 78.1% for pICR.There were no significant differences in outcomes between the cCR and pCR groups (P = 0.810); however, the pICR group exhibited poorer outcomes (P = 0.002). Conclusion:This study shows no significant long-term oncological differences between patients who exhibited cCR and those who experienced pCR.